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Description of macrophage activation is currently contentious and confusing. Like the biblical Tower of
Babel, macrophage activation encompasses a panoply of descriptors used in different ways. The lack of
consensus on how to define macrophage activation in experiments in vitro and in vivo impedes progress
inmultiple ways, including the fact that many researchers still consider there to be only two types of activated
macrophages, often termed M1 and M2. Here, we describe a set of standards encompassing three princi-
ples—the source of macrophages, definition of the activators, and a consensus collection of markers to
describe macrophage activation—with the goal of unifying experimental standards for diverse experimental
scenarios. Collectively, we propose a common framework for macrophage-activation nomenclature.Overview
Activation of macrophages has emerged as a key area of immu-
nology, tissue homeostasis, disease pathogenesis, and resolving
and nonresolving inflammation (Biswas and Mantovani, 2010;
Gordon and Martinez, 2010; Lawrence and Natoli, 2011; Manto-
vani et al., 2008; Mantovani et al., 2005; Martinez et al., 2008;
Murray and Wynn, 2011b; Nathan and Ding, 2010; Wynn et al.,
2013). Over the last several years, diverse terms have been
applied to macrophage activation and ‘‘polarization,’’ where a
stimulus such as a cytokine or toll-like receptor (TLR) agonist pro-
duces distinct patterns of gene and protein expression. Here, we14 Immunity 41, July 17, 2014 ª2014 Elsevier Inc.use the term ‘‘activation’’ to mean the perturbation of macro-
phages with exogenous agents in the same vein as many use
‘‘polarization.’’ We also note the ability of macrophages to
change their activation states in response to growth factors
(e.g., CSF-1 and GM-CSF) and external cues, such as cytokines,
microbes, microbial products, and other modulators, including
nucleotide derivatives, antibody-Fc receptor stimulation, gluco-
corticoids, infection, phagocytosis, and potentially any other en-
tity capable of being recognized by macrophages. Because
macrophage activation is involved in the outcome of many dis-
eases, including metabolic diseases, allergic disorders (such as
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terial, parasitic, fungal, and viral infections,we need to establish a
common language for describing the properties of the macro-
phages under investigation.
Background to the Problem
We note widespread use of at least four definitions of macro-
phage activation, including terms such asM1 andM2, alternative
and classical activation, ‘‘regulatory’’ macrophages, and subdi-
visions originating from the parent terms. The origins of these
terms originated in the early 1990s when differential effects of
interleukin-4 (IL-4) in comparison to those of interferon g (IFN-
g) and/or lipopolysaccharide (LPS) onmacrophage gene expres-
sion were described (Martinez and Gordon, 2014; Stein et al.,
1992). Compared to IFN-g, IL-4 was described to induce ‘‘alter-
native activation.’’ It should be noted that the term ‘‘classical’’
activation, which originally referred to macrophages stimulated
with IFN-g, is now interchangeably used with IFN-g and TLR
stimulation (Martinez and Gordon, 2014). The second definition
came several years later when Mills proposed the M1-M2
terminology (Mills et al., 2000). Mills’s idea originated from the
differential metabolism of arginine between macrophages from
C57BL/6 andmacrophages fromBalb/cmice, an effect he corre-
lated with differences between T helper 1 (Th1) and Th2 cell re-
sponses in the same strains. Mills and colleagues went further
and proposed that the M1-M2 dichotomy was an intrinsic prop-
erty of macrophages associated with transitions from inflam-
mation to healing, would occur in the absence of an adaptive
immune response, and arose early in evolution (Mills, 2012).
Several lines of evidence suggest that this theory requires
rethinking. First, C57BL/6 mice bear a deletion in the promoter
of Slc7a2, encoding the key arginine transporter in macro-
phages, causing large differences in arginine utilization between
C57BL/6 and BALB/c mice. This genetic difference between
the strains was not known at the time that Mills’s hypothesis
was published and was therefore not taken into account
(Sans-Fons et al., 2013). Second, although Mills’s notion on
‘‘innate’’ shifts in macrophage activation might be true, most
immunologists are concerned with immunity in the presence of
lymphocytes, which profoundly affect the activation state of
macrophages through cytokine secretion. Third, no molecular
definition has yet accounted for an ‘‘innate’’ M1-to-M2 transition,
although new information from epigenetics and metabolism
(see below) might provide a means of dissecting intrinsic macro-
phage activation states.
The third set of nomenclature (M2a, M2b, etc.) expanded the
M1-M2 definitions to account for different activation scenarios
and was balanced by the idea that activation exists on a spec-
trum and cannot be easily binned into defined groups (Biswas
and Mantovani, 2010; Edwards et al., 2006; Mantovani et al.,
2005; Martinez and Gordon, 2014; Stout et al., 2005; Stout and
Suttles, 2004). The fourth definition refers to macrophages
grown in GM-CSF-1 as M1 and macrophages grown in CSF-1
as M2 (Joshi et al., 2014). Notably, significant differences have
been documented in the transcriptomes of macrophage popu-
lations primarily generated with the use of CSF-1 or GM-CSF,
with and without exogenous perturbation (Fleetwood et al.,
2009), but there is no compelling evidence to assign CSF-1- or
GM-CSF-derived macrophages as M1 or M2.The diversity of terminology and inconsistent use of markers
to describe macrophage activation impedes research in several
ways. First, researchers entering the field encounter confusion
about which terms to use and which markers are representative
of their experimental or human-based system;many researchers
might erroneously consider there to be only ‘‘two types of mac-
rophages.’’ Second, established researchers in the field have yet
to agree on nomenclature or standards for describing activation.
Third, grant and manuscript writers and their reviewers, funding
and regulatory agencies, and journal editors can be exasper-
ated at the breadth of terminology in use. Fourth, the lack of
experimental standards impedes studies where comparisons
are required (e.g., microarray and proteomic data sets). Fifth,
deployment of therapeutic macrophage modulators requires
that standards be translatable across disciplines so that phar-
maceutical and regulatory bodies can draw meaningful compar-
isons in terms of diagnostic or efficacy metrics. A sixth and final
issue is the diversity in macrophage activation across species
(discussed briefly below).
To address the obstacles and pitfalls in describing macro-
phage activation and in achieving experimental standards, a
small group of macrophage biologists met informally at the Inter-
national Congress of Immunology in Milan in August 2013. We
discussed the issues surrounding terminology and set out to pro-
vide an initial set of nomenclature and experimental guidelines. A
draft letter was then circulated to a broader group of researchers
active in this area. In this perspective, we do not attempt to cap-
ture everyone who has published on macrophage activation and
polarization; rather, we aim to attain consensus about the prob-
lems within the field and to propose solutions. As such, discus-
sion and revision will be essential for refining the properties and
mechanisms of macrophage polarization.
Recommendations
A Reproducible Experimental Standard
We concluded that a starting point was to frame a nomencla-
ture system within a reproducible in vitro experimental standard.
CSF-1-cultured macrophages from murine bone marrow and
human peripheral-blood monocytes remain the predominant
in vitro systems used for generating macrophages and therefore
will be used as references (Figure 1A). Other commonly used
macrophage sources are peritoneal macrophages (resident or
elicited) from mice and GM-CSF-cultured macrophages from
murine bone marrow (Figure 1A), and each of these can be per-
turbed to generate activated populations of macrophages with
gene-expression profiles overlapping those of CSF-1-generated
cells. On this basis, the culture conditions for generating the
two paradigmatic in vitro M1 andM2 populations are straightfor-
ward, i.e., postdifferentiation stimulation with IFN-g or IL-4. IL-4
and IFN-g often exert clear-cut antagonistic effects on macro-
phage polarization mediated by STAT6 and STAT1, respectively.
Furthermore, IL-4 and IFN-g induce defined and comprehen-
sively investigated macrophage subpopulations (Lawrence and
Natoli, 2011; Mills, 2012; Rutschman et al., 2001; Taub and
Cox, 1995; Wynn et al., 2013).
Recommendation for Minimal Reporting Standards
Incomplete descriptions of howmacrophages are isolated, stim-
ulated, and analyzed are contrary to the value of replication and
reproducibility across laboratories. To this end, macrophagesImmunity 41, July 17, 2014 ª2014 Elsevier Inc. 15
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Table 1. Reporting Standards for In Vitro Experiments
Parameter Notes
Mouse strain how the bone marrow is isolated and processed
Starting cell number, media, and supplements media (DMEM versus RPMI) have substantial effects of growth rate, development,
and activation status
Tissue-culture conditions different types of plastic affect macrophage growth and activation; tissue-culture
conditions should be documented for reproducibility
Time of culture the precise conditions used and whether cytokines and/or media are supplemented
during the culture period
Source and concentration of differentiation cytokines the source and concentration of CSF-1
Macrophage yield the yield relative to the starting number should be recorded
Activation conditions variables include whether macrophages are rested prior to activation and how,
whether CSF-1 is present in the activation cultures, the source and concentrations
of the activating agents, and the time to assay
Processing and analysis how the cells are processed and what marker readouts are used
Immunity
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reporting standards encapsulated in Table 1. With these stan-
dards as a guide, in vitro experiments from different labora-
tories can be directly compared. Finally, we favor the use of
purified endotoxin-free recombinant CSF-1 rather than L-cell-
conditioned medium as the source of CSF-1 to generate
bone-marrow-derived macrophages because the latter is not
readily defined and can vary from batch to batch. For example,
L-cell-conditioned medium contains variable amounts of type I
interferons that could cause confounding effects in subsequent
activation experiments (Warren and Vogel, 1985).
Define the Activator
In general, given that diverse mediators have been used alone
or in various combinations for the generation of polarized
macrophage populations, we propose that researchers describe
stimulation scenarios and adopt a nomenclature linked to the
activation standards, i.e., M(IL-4), M(Ig), M(IL-10), M(GC),
M(IFN-g), M(LPS), and so forth (Figure 1B). Such a system avoids
the complexity of M2a, M2b, etc., where one laboratory might
experimentally define activation differently than another, and
allows new activation conditions to be compared and contrasted
with these core examples. Figure 1 also depicts the concept
of a ‘‘spectrum’’ of activation to denote activation ‘‘states’’
commonly observed (Mosser and Edwards, 2008; Stout et al.,
2005; Stout and Suttles, 2004; Xue et al., 2014). The employment
of the spectrum concept is useful where ambiguity exists or
when researchers are operating outside the in vitro CSF-1
schema described above. In summary, we note that standardsFigure 1. Framework for Describing Activated Macrophages
(A) Examples of widely used macrophage preparations. CSF-1-grown mouse adh
the exemplars for marker evaluation and standardized activation conditions. Mac
(DC) population is also present depending on the culture conditions. In mice,
macrophage populations with differing yields and properties, whereas many orga
(B) Marker systems for activated macrophages. Shown are functional subdivision
derived CSF-1 macrophages with the existing M1-M2 spectrum concept (Martin
Stimulation conditions are IL-4, immune complexes (Ic), IL-10, glucocorticoids (G
and IFN-g, and IFN-g alone. Marker data were drawn from awide range of publish
consensus (Edwards et al., 2006; Fleetwood et al., 2009; Gratchev et al., 2008; Gu
Shirey et al., 2014; Shirey et al., 2010; Xue et al., 2014). An asterisk indicates corro
shown).
(C) Using genetics to aid in macrophage-activation studies. Mutations in Akt1 an
whereas mutations in Akt2 and Klf6 show the reverse phenotype. Mutations in St
and/or amplitude of activation.need to be simple for adoption but at the same time not cause
sudden conceptual shifts. Therefore, researchers should
consider harnessing the terminology and markers for CSF-1-
grown macrophages activated under defined conditions as a
reference standard (Xue et al., 2014). Where ambiguity exists—
for example, in a macrophage population isolated from an in vivo
system—researchers should emphasize the marker combina-
tions used and state the closest relative(s) along the spectrum
shown in Figure 1 (discussed below).
Terms to Avoid
We propose that the term ‘‘regulatory’’ macrophages should be
avoided because all macrophages are regulatory in some capac-
ity. The use of macrophages derived from mice with specific
targeted mutations that prevent development of an M(IL-4) pro-
file (e.g., through the use of IL-4Ra- or STAT6-deficient macro-
phages) is recommended to confirm a specific phenotype.
Some researchers often ascribe the subset terminology M1
and M2 to GM-CSF- and CSF-1-generated macrophages,
respectively; such terminology should be abandoned. When
CSF-1 or GM-CSF is used for generating activated macrophage
populations, it should be clearly indicated. A further complication
is that GM-CSF cultures contain substantial numbers of CD11c+
cells with distinct antigen-presenting activities that need to be
accounted for in gene profiling or functional analyses.
Markers of Activation
CD4 defines CD4+ Th cells. Within CD4+ cells, Foxp3 defines
regulatory T cells. These are just two examples of markers
defining cell lineages. By contrast, macrophage activation iserent macrophages from bone marrow (BM) or CD14+ monocytes are used as
rophages can also be generated with GM-CSF, where a CD11c+ dendritic cell
thioglycollate injection followed by peritoneal lavages is used for generating
n systems in mice and humans are sources of tissue-infiltrating macrophages.
s according to stimulation of mouse CSF-1 macrophages or human monocyte-
ez and Gordon, 2014; Mosser and Edwards, 2008; Stout and Suttles, 2004).
C) with transforming growth factor b (TGF-b), glucocorticoids alone, LPS, LPS
ed and unpublished data from the authors’ laboratories and represent a starting
ndra et al., 2014; Krausgruber et al., 2011; Lang et al., 2002; Shirey et al., 2008;
boration of human IL-4 genes by deep sequencing (K.A.S. and S.N.V., data not
d Klf4 cause a ‘‘switch’’ to M(LPS)- and M(IFN-g)-associated gene expression,
at6, Ppard, Pparg, and Irf4 and IRF5 depletion are involved in the maintenance
Immunity 41, July 17, 2014 ª2014 Elsevier Inc. 17
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of genes) depending on the specific stimuli, but none define
a sublineage or activation state of macrophages. To the
researcher outside the macrophage sphere, marker use prob-
ably appears confusing because immunologists are accustomed
to tight marker-lineage association. An example of problematic
marker use is expression of Arginase-1 (Arg1) as a ‘‘marker’’
for M2 or M(IL-4) spectrummacrophages, which has led to inter-
pretive problems because Arg1 is also induced in M1 spectrum
macrophages, expressed in some resident macrophage popu-
lations, and highly induced in mycobacteria-infected macro-
phages, further emphasizing the need for criteria encompassing
multiple markers (El Kasmi et al., 2008). Accordingly, we favor
an approach using combinations of markers (or a lack of
marker expression) to ascribe activation outcomes as outlined
in Figure 1B. Clearly, there is significant scope to expand upon
marker assignment such as transcription factor and cell-surface
marker combinations within the standardized experimental
framework proposed here, and this should serve as a starting
cartography for the field.
Translation to In Vivo Experiments
When isolating macrophages from tissue and analyzing their
activation state, each laboratory will confront a familiar problem:
what do we call them? What if there are different populations
present? Our recommendation is to acquire sufficient evidence
to place a given population within the framework shown in
Figure 1. It seems unlikely that a particular in vivo scenario will
fall exactly within the groups in Figure 1. However, as more
macrophage populations are dissected ex vivo, more informa-
tion will accumulate to help us understand the general and spe-
cific nature of in vivo macrophage activation.
Ex Vivo Characterization of Macrophage Activation
Each laboratory has individualized macrophage isolation proce-
dures. Because of the breadth of conditions used, we favor
describing in detail how macrophages are isolated, which tissue
and pathological or homeostatic condition they are from, and
which marker combinations are used for ascertaining macro-
phage activation. All authors stress the need for rapid isolation
techniques to preserve the underlying phenotype quickly and
without additional ex vivo culture. Advances in technologies for
in situ gene expression within individual tissues and cells will
most likely advance the understanding of spatial macrophage
activation. Regardless of the technology employed, combina-
tions of markers need to be applied to the populations being
analyzed, and a full description of the isolation techniques needs
to be provided. For example, the Immgen Consortium has a
mandate for isolation and sorting conditions for immune cells,
and we favor their degree of descriptive rigor for ex vivo macro-
phages (Gautier et al., 2012). Another complication from ex vivo
analysis of macrophage activation is plasticity across different
disease stages. For example, in obesity research, macrophages
residing in adipose tissue are thought to becomemore proinflam-
matory as fat accumulates and thus fall toward theM1 end of the
activation spectrum (Wynn et al., 2013). In atherosclerosis,
resolution of lesions is associated with the reverse: macrophage
populations on the M1 spectrum convert to the M2 part of the
spectrum without evidence of local STAT6 activation by IL-4 or
IL-13 (Moore et al., 2013). One solution to the problem of18 Immunity 41, July 17, 2014 ª2014 Elsevier Inc.describing macrophage activation in scenarios in vivo is to begin
with an explicit description of the populations under investigation
and how they were isolated (as Immgen defines, for example).
Markers can then be used to reflect the perturbations they have
encountered. For example, Arg1hiRetnlahipSTAT6+pSTAT1
could be used to enhance the description of a specific lung
macrophage population isolated from a Th2-cell-type-driven
disease and thus be reasonably related to the M(IL-4) cells
(Figure 1B). Reporting the time points of ex vivo macrophage
isolation and analysis are therefore mandatory in the description
of tissue- and disease-associated macrophage populations.
Translation to Human Macrophages
How can we define and categorize activated human macro-
phages? This question continues to confound researchers in
part because human macrophages are generally isolated from
blood monocytes as opposed to bone marrow or tissues
commonly used in murine studies. This distinction is particularly
important with the new knowledge that many tissue-resident
populations are not of bone marrow origin (Sieweke and Allen,
2013). Many of the markers used for murine macrophages
have not translated to human macrophages. Plausible reasons
for these discrepancies have been discussed (Murray and
Wynn, 2011a), but it is worth emphasizing that no study has
systematically compared the responses of blood-monocyte-
derived macrophages from mice and humans in a side-by-side
manner. We expect a range of interspecies variability on macro-
phage activation to reflect different evolutionary outcomes
sculpted by different pathogens, diets, longevity, etc. Despite
the variables involved, experimental rigor can be used in the
search for information about human (and any other species)
macrophage biology according to the principles and practices
outlined here. Recently, systematic studies have begun to
explore the conservation between macrophages from different
species, including swine, where large numbers of different tissue
macrophages can be isolated (Fairbairn et al., 2011; Martinez
et al., 2013; Schroder et al., 2012; Xue et al., 2014). Therefore,
researchers should describe how they generate their macro-
phages and subsequently stimulate them. When microarray,
deep sequencing, and proteomic studies are combined to inter-
rogate human macrophages, a consensus will emerge about
which pathways of human macrophage activation are amenable
to new drug discovery.
Genetics to Alter Activation States
Recent work has identified genetic modifications producing
shifts in activation phenotype. For example, deletion of tran-
scription factor IRF4 or KLF6 fails to makeM(IL-4) macrophages,
whereas PPARg and PPARv are required for the amplitude of the
M(IL-4) state (Chawla, 2010; Date et al., 2014; Ivashkiv, 2013).
Ablation of proteins involved in anabolic growth, such AKT2
and PTEN, enhances an activation state where gene expression
is linked to M(IL-4) macrophages, whereas deletion of TSC1, an
inhibitor ofmTOR, causes the opposite effect (Arranz et al., 2012;
Byles et al., 2013; Yue et al., 2014). Other mutations in the mTOR
pathway have produced disparate results. However, using the
principles described here for systematic investigation of mTOR
pathway mutants will most likely resolve why rapamycin-treated
macrophages and macrophages from Raptor, Rictor, and TSC1
mutants have diverse phenotypes (Ai et al., 2014; Byles et al.,
2013; Festuccia et al., 2014; Weichhart et al., 2008). Some of
Immunity
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these and related mutants will be increasingly useful for defining
activation states. Finally, it is important to recognize the effect of
timing on altering the activation state. Several parameters can
affect activation state across time; these include (1) removal of
the stimulus, (2) enforcement of feedback and feed-forward
signaling loops, including autocrine production of cytokines,
and (3) epigenetic and/or developmental effects built into the
life history of a macrophage (Ivashkiv, 2013; Lawrence and
Natoli, 2011; Porta et al., 2009). This would go back to Mills’s
notion of an activated-to-healing transition.
Perspectives and Conclusions
Understanding macrophage behavior is a keystone of decipher-
ing disease pathogenesis. It is straightforward to isolate and
propagate macrophages, facilitating their links to disease. By
contrast, nomenclature and standardization issues are stunting
progress because a lingua franca has yet to be established
and accepted. We hope our attempts are a starting point to
resolve some of the immediate issues. We emphasize that our
goal is to initiate dialog rather than act as arbiters of language
and experiment. In doing so, we hope scientists new to
macrophage biology, established researchers, pharmaceutical
companies, and regulatory agencies can appreciate the history
of our field and the need for a common framework open to
frequent revision.
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